#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Faecal microbial transplantation in inflammatory bowel disease


Authors: J. Březina;  L. Bajer;  J. Špičák;  P. Drastich
Authors‘ workplace: Klinika hepatogastroenterologie, Transplantcentrum, IKEM, Praha
Published in: Gastroent Hepatol 2016; 70(1): 51-56
Category: IBD: Review Article
doi: https://doi.org/10.14735/amko201651

Overview

The etiopathogenesis of inflammatory bowel disease (IBD) is not yet fully understood. One theory proposes that IBD onset is an overreaction of the gut immune system to some parts of the gut microbiome. Thus, one therapeutic approach is to employ a faecal microbiota transplant (FMT) to change the composition of the gut microbiome. FMT involves transplanting fecal matter or stool from a healthy donor to a recipient, leading to the reestablishment of gut microbiome homeostasis for a certain period of time. FMT is a standard, clinical procedure that is highly effective for the treatment of recurrent clostridium difficile colitis. FMT in IBD is an experimental method used only in clinical trials. Recent studies have shown that FMT has a highly variable effect on disease remission and clinical response. Two randomized control studies providing no compelling evidence for the effectiveness of FMT in patients with ulcerative colitis have been published recently. However, studies of FMT treatment of ulcerative colitis suggest that beneficial effects depend on the donor having a rich and diversified microbiome, method of administration, and the frequency of FMT. Finally, the effectiveness of FMT treatment of Crohn’s disease has not yet been investigated thoroughly; however, the data so far indicate minimal beneficial effects of FMT for Crohn’s disease patients. To sum up, FMT is a safe method with minimum adverse effects when the donor is carefully selected. Although FMT treatment of ulcerative colitis is only moderately effective, it represents a safe and promising therapeutic approach. However, there is an urgent need for a more thorough investigation of FMT in larger cohorts of patients to clarify the effectiveness, remission induction rate, necessary number of FMT, long term safety, and proper application of FMT.

Key words:
Crohn’s disease – faecal bacterial transplantation – inflammatory bowel disease – clostridium difficile colitis – microbiome – ulcerative colitis

The author declares he has no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE „uniform requirements“ for biomedical papers.

Submitted:
15. 1 .2016

Accepted:
29. 1. 2016


Sources

1. Frank DN, Pace NR. Gastrointestinal microbio­logy enters the metagenomics era. Curr Opin Gastroenterol 2008; 24(1): 4– 10.

2. Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010; 464(7285): 59– 65. doi: 10.1038/ nature08821.

3. Zhang F, Luo W, Shi Y et al. Should we standardize the 1,700-year-old fecal microbio­ta transplantation? Am J Gastroenterol 2012; 107(11): 1755. doi: 10.1038/ ajg.2012.251.

4. Eiseman B, Silen W, Bascom GS et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958; 44(5): 854– 859.

5. van Nood E, Vrieze A, Nieuwdorp M et al. Duodenal infusion of donor feces for recur­rent Clostridium dif­ficile. N Engl J Med 2013; 368(5): 407– 415. doi: 10.1056/ NEJMoa1205037.

6. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbio­ta transplantation (fecal bacteriotherapy) for recur­rent Clostridium dif­ficile infection. Clin Infect Dis 2011; 53(10): 994– 1002. doi: 10.1093/ cid/ cir632.

7. Hamilton MJ, Weingarden AR, Sadow­sky MJ et al. Standardized frozen preparation for transplantation of fecal microbio­ta for recur­rent Clostridium dif­ficile infection. Am J Gastroenterol 2012; 107(5): 761– 767. doi: 10.1038/ ajg.2011.482.

8. Postigo R, Kim JH. Colonoscopic versusnasogastric fecal transplantation for the treat­-ment of Clostridium dif­ficile infection: a review and pooled analysis. Infection 2012; 40(6): 643– 648. doi: 10.1007/ s15010-012-0307-9.

9. Persky SE, Brandt LJ. Treatment of recur­rent Clostridium dif­ficile- as­sociated diar­rhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000; 95(11): 3283– 3285.

10. Yoon SS, Brandt LJ. Treatment of refractory/ recur­rent C. dif­ficile-as­sociated dis­ease by donated stool transplanted via colonoscopy: a case series of 12 patients. J Clin Gastroenterol 2010; 44(8): 562– 566. doi: 10.1097/ MCG.0b013e3181dac035.

11. Angelberger S, Reinisch W, Makristathis Aet al. Temporal bacterial com­munity dynamics vary among ulcerative colitis patients after fecal microbio­ta transplantation. Am J Gastroenterol 2013; 108(10): 1620– 1630. doi: 10.1038/ ajg.2013.257.

12. Youngster I, Rus­sell GH, Pindar C et al.Oral, capsulized, frozen fecal microbio­ta transplantation for relaps­ing Clostridium dif­ficile infection. Jama 2014; 312(17): 1772– 1778. doi: 10.1001/ jama.2014.13875.

13. Schwartz M, Gluck M, Koon S. Norovirus gastroenteritis after fecal microbio­ta transplantation for treatment of Clostridium dif­ficile infection despite asymp­tomatic donors and lack of sick contacts. Am J Gastroenterol 2013; 108(8): 1367. doi: 10.1038/ ajg.2013.164.

14. Brandt LJ, Aroniadis OC, Mel­low M et al.Long-term fol­low-up of colonoscop­icfecal microbio­ta transplant for recur­rent Clostridium dif­ficile infection. Am J Gastroenterol 2012; 107(7): 1079– 1087. doi: 10.1038/ ajg.2012.60.

15. Nagalingam NA, Lynch SV. Role of the microbio­ta in inflam­matory bowel diseases. Inflamm Bowel Dis 2012; 18(5): 968– 984. doi: 10.1002/ ibd.21866.

16. DuPont AW, DuPont HL. The intestinal microbio­ta and chronic disorders of the gut. Nat Rev Gastroenterol Hepatol 2011; 8(9): 523– 531. doi: 10.1038/ nrgastro.2011.133.

17. Sartor RB. Microbial influences in inflam­matory bowel diseases. Gastroenterology 2008; 134(2): 577– 594. doi: 10.1053/ j.gastro.2007.11.059.

18. Vernia P. Butyrate in the treatment of ulcerative colitis. Digest Liver Dis 2007; 1 (Suppl 1): 27– 30. doi: 10.1016/ S1594-5804(08)60008-X.

19. Hamer HM, Jonkers DM, Vanhoutvin SA et al. Ef­fect of butyrate enemas on inflam­mation and antioxidant status in the colonic mucosa of patients with ulcerative colitis in remis­sion. Clin Nutr 2010; 29(6): 738– 744. doi: 10.1016/ j.clnu.2010.04.002.

20. Lix LM, Graff LA, Walker JR et al. Longitudinal study of quality of life and psychological function­ing for active, fluctuating, and inactive disease patterns in inflam­matory bowel disease. Inflamm Bowel Dis 2008; 14(11): 1575– 1584. doi: 10.1002/ ibd.20511.

21. Ben­net JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet 1989; 1(8630): 164.

22. Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbio­ta transplantation in the management of inflam­matory bowel disease. Aliment Pharmacol Ther 2012; 36(6): 503– 516. doi: 10.1111/ j.1365-2036.2012.05220.x.

23. Ros­sen NG, MacDonald JK, de Vries EM et al. Fecal microbio­ta transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol 2015; 21(17): 5359– 5371. doi: 10.3748/ wjg.v21.i17.5359.

24. Vermeire S, Joos­sens M, Verbeke K et al. Donor species richness determines faecal microbio­ta transplantation success in inflam­matory bowel disease. J Crohns Colitis 2015; jjv203. doi: 10.1093/ ecco-jcc/ jjv203.

25. Moayyedi P, Surette MG, Kim PT et al. Fecal microbio­ta transplantation induces remis­sion in patients with active ulcerative colitis in a randomized control­led trial. Gastroenterology 2015; 149(1): 102– 109. doi: 10.1053/ j.gastro.2015.04.001.

26. Ros­sen NG, Fuentes S, van der Spek MJet al. Findings from a randomized control­led trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015; 149(1): 110–118. doi: 10.1053/ j.gastro.2015.03.045.

27. Gordon H, Harbord M. A patient with severe Crohn‘s colitis responds to Faecal Microbio­ta Transplantation. J Crohn Colitis 2014; 3(8): 256– 257. doi: 10.1016/ j.crohns.2013.10.007.

Labels
Paediatric gastroenterology Gastroenterology and hepatology Surgery

Article was published in

Gastroenterology and Hepatology

Issue 1

2016 Issue 1

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#